A Major Milestone for Quantum BioPharma & Lucid-MS Quantum BioPharma (NASDAQ: QNTM) is moving Lucid-MS forward toward Phase 2, entering into a Study Start-Up Agreement with the PPD™ Clinical Research Business of Thermo Fisher Scientific. Following FDA clearance to proceed, formal study start-up activities are now underway for the planned Phase 2 multiple sclerosis trial. A significant step forward in our mission to develop a potentially first-in-class neuroprotective approach for MS. The next chapter for Lucid-MS starts now. #QNTM #QuantumBioPharma #LucidMS #MultipleSclerosis #Phase2 #Biotech #Innovation #ThermoFisherScientific

Big News for unbuzzd™ Quantum BioPharma is pleased to announce the appointment of visionary entrepreneur Michael “Zappy” Zapolin as CEO of Unbuzzd Wellness Inc. From Wall Street to pioneering internet ventures and next-generation wellness, Zappy brings decades of entrepreneurial experience, brand-building expertise and an extensive network to unbuzzd. His mandate: help finance and list Unbuzzd on a stock exchange and lead the execution of a nationwide U.S. commercial marketing and product rollout. Science-backed. Clinically validated. Built for a massive consumer opportunity. unbuzzd™ is backed by a peer-reviewed clinical study supporting its ability to accelerate alcohol metabolism, restore mental clarity and reduce hangover symptoms. As Zappy puts it: “I believe unbuzzd has the potential to help millions of lives, and I’m honored to help bring it forward.” The next chapter of unbuzzd™ starts now. 🌐 Discover unbuzzd: unbuzzd.com 📈 Quantum BioPharma Ltd. — NASDAQ: QNTM | FRA: 0K91 Advancing Science. Saving Lives. #QuantumBioPharma #QNTM #unbuzzd #ZappyZapolin #Wellness #FunctionalBeverage #AlcoholRecovery #ConsumerHealth #Innovation #Biotech #NASDAQ